Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide ER for Albuminuria in T2DM
NCT03029351Phase 4Terminated
- Sponsor
- University at Buffalo
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide in diabetic nephropathy (DN), type 2 diabetes mellitus (T2DM), sponsored by University at Buffalo. Started Jan 2017; status: terminated.
02
Drugs
exenatide
03
Conditions
diabetic nephropathy (DN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03029351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029351.